ENABLING INHALABLE RNA THERAPY

RNhale GmbH is a biotech spin-off revolutionizing the pharmaceutical landscape with its proprietary platform technology for formulating RNA-loaded lipid nanoparticles as an inhalable dry powder. The company targets pulmonary diseases, including severe asthma, COPD, viral infections, and idiopathic fibrosis, all of which present vast addressable markets and significant medical needs.

Founded in 2023.

www.rnhale.com


Vision of RNhale:

"We’re honored to be part of the MAXL community. Being accepted into this vibrant innovation hub gives us access to state-of-the-art facilities, valuable networks, and the ideal support to accelerate our mission of transforming pulmonary RNA delivery."


The management team of RNhale: